1. Home
  2. UTHR vs RCI Comparison

UTHR vs RCI Comparison

Compare UTHR & RCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • RCI
  • Stock Information
  • Founded
  • UTHR 1996
  • RCI 1960
  • Country
  • UTHR United States
  • RCI Canada
  • Employees
  • UTHR N/A
  • RCI N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • RCI Cable & Other Pay Television Services
  • Sector
  • UTHR Health Care
  • RCI Telecommunications
  • Exchange
  • UTHR Nasdaq
  • RCI Nasdaq
  • Market Cap
  • UTHR 14.4B
  • RCI 13.4B
  • IPO Year
  • UTHR 1999
  • RCI N/A
  • Fundamental
  • Price
  • UTHR $308.00
  • RCI $25.44
  • Analyst Decision
  • UTHR Buy
  • RCI Buy
  • Analyst Count
  • UTHR 12
  • RCI 4
  • Target Price
  • UTHR $392.00
  • RCI $67.00
  • AVG Volume (30 Days)
  • UTHR 439.7K
  • RCI 1.1M
  • Earning Date
  • UTHR 04-30-2025
  • RCI 04-23-2025
  • Dividend Yield
  • UTHR N/A
  • RCI 5.57%
  • EPS Growth
  • UTHR 18.86
  • RCI 196.65
  • EPS
  • UTHR 25.10
  • RCI 2.26
  • Revenue
  • UTHR $2,994,100,000.00
  • RCI $14,386,892,540.00
  • Revenue This Year
  • UTHR $11.45
  • RCI $4.33
  • Revenue Next Year
  • UTHR $6.11
  • RCI $2.20
  • P/E Ratio
  • UTHR $12.27
  • RCI $11.25
  • Revenue Growth
  • UTHR 19.84
  • RCI 1.50
  • 52 Week Low
  • UTHR $260.41
  • RCI $23.18
  • 52 Week High
  • UTHR $417.82
  • RCI $41.84
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 57.25
  • RCI 46.97
  • Support Level
  • UTHR $290.02
  • RCI $25.27
  • Resistance Level
  • UTHR $319.40
  • RCI $26.18
  • Average True Range (ATR)
  • UTHR 10.02
  • RCI 0.54
  • MACD
  • UTHR 2.72
  • RCI 0.10
  • Stochastic Oscillator
  • UTHR 69.99
  • RCI 50.66

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About RCI Rogers Communication Inc.

Rogers Communications is the largest wireless service provider in Canada, with its more than 11 million subscribers equating to one third of the total Canadian market. Its wireless business accounted for more than half of total revenue and has increasingly been providing a bigger portion of total company sales over the last several years. Rogers' cable segment, which provides about 35% of total revenue after acquiring Shaw, offers home internet, television, and landline phone service to consumers and businesses. Remaining sales come from Rogers' media unit, which owns and operates various television and radio stations and the Toronto Blue Jays. Rogers' significant exposure to sports also includes ownership stakes in the Toronto Maple Leafs, Raptors, FC, and Argonauts.

Share on Social Networks: